{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T09:40:45Z","timestamp":1789465245619,"version":"build-2803163510"},"reference-count":30,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,9,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>The comparative effects of mineralocorticoid receptor antagonists (MRAs) in heart failure with preserved ejection fraction (HFpEF) or mildly reduced ejection fraction (HFmrEF) remain uncertain, including potential differences between steroidal MRAs and finerenone. This Bayesian network meta-analysis aimed to compare the efficacy and safety of finerenone, eplerenone, and spironolactone vs placebo in HFpEF\/HFmrEF.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We searched Pubmed, Cochrane, and Embase for studies focused on MRA treatment in HFpEF and\/or HFmrEF. Eight randomized controlled trials enrolling adults with HFpEF or HFmrEF (LVEF \u226540%) were analysed in a fixed-effects Bayesian network meta-analysis. Risk ratios (RRs) with 95% credible intervals (CrIs) were estimated for hospitalization for HF, cardiovascular death, and hyperkalaemia. Heterogeneity was assessed using I2.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Across a network comprising 10 644 patients, mean age 70.2; 48% women; mean LVEF 54.9%, finerenone reduced hospitalization for HF vs placebo (RR 0.84; 95% CrI 0.75\u20130.93), whereas spironolactone (RR 0.86; 95% CrI 0.73\u20131.01) and eplerenone (RR 0.86; 95% CrI 0.59\u20131.26) showed non-significant effects. None of the MRAs achieved a statistically significant reduction in cardiovascular mortality vs placebo: finerenone (RR 0.93; 95% CrI 0.78\u20131.10), spironolactone (RR 0.93; 95% CrI 0.76\u20131.14), and eplerenone (RR 1.10; 95% CrI 0.29\u20135.69). All MRAs increased hyperkalaemia vs placebo: finerenone (RR 2.06; 95% CrI 1.77\u20132.41), spironolactone (RR 2.13; 95% CrI 1.81\u20132.53), and eplerenone (RR 2.17; 95% CrI 0.75\u20137.97).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In HFpEF\/HFmrEF, finerenone was the only MRA to significantly reduce hospitalization for HF, while no agent significantly reduced cardiovascular mortality and hyperkalaemia risk increased across therapies. Overall, finerenone may offer the most favourable efficacy\u2013safety balance among MRAs, pending confirmation in larger dedicated trials.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ejhf\/xuag083","type":"journal-article","created":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T15:45:00Z","timestamp":1773330300000},"page":"473-483","source":"Crossref","is-referenced-by-count":4,"title":["Finerenone, eplerenone, and spironolactone in heart failure with preserved ejection fraction: a Bayesian network meta-analysis of efficacy and safety"],"prefix":"10.1093","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-4207-5697","authenticated-orcid":false,"given":"Vitor","family":"Bagattoli","sequence":"first","affiliation":[{"name":"Medical Sciences Research Center, University Center for the Development of the Alto Vale do Itaja\u00ed , Rio do Sul, Santa Catarina ,","place":["Brazil"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-0021-8258","authenticated-orcid":false,"given":"Helena Schell","family":"dos Santos","sequence":"additional","affiliation":[{"name":"Medical Sciences Research Center, University Center for the Development of the Alto Vale do Itaja\u00ed , Rio do Sul, Santa Catarina ,","place":["Brazil"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-7271-4845","authenticated-orcid":false,"given":"Juliana","family":"Giorgi","sequence":"additional","affiliation":[{"name":"S\u00edrio-Liban\u00eas Hospital , S\u00e3o Paulo, S\u00e3o Paulo ,","place":["Brazil"]},{"name":"Albert Einstein Hospital , S\u00e3o Paulo, S\u00e3o Paulo ,","place":["Brazil"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-1461-7185","authenticated-orcid":false,"given":"Pedro Gomes","family":"Batista","sequence":"additional","affiliation":[{"name":"Federal University of Para\u00edba , Jo\u00e3o Pessoa, Para\u00edba ,","place":["Brazil"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9998-6492","authenticated-orcid":false,"given":"Samantha Cristiane","family":"Lopes","sequence":"additional","affiliation":[{"name":"Medical Sciences Research Center, University Center for the Development of the Alto Vale do Itaja\u00ed , Rio do Sul, Santa Catarina ,","place":["Brazil"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0170-7211","authenticated-orcid":false,"given":"Marcelo Vier","family":"Gambetta","sequence":"additional","affiliation":[{"name":"Medical Sciences Research Center, University Center for the Development of the Alto Vale do Itaja\u00ed , Rio do Sul, Santa Catarina ,","place":["Brazil"]},{"name":"Regional Alto Vale Hospital , Rio do Sul, Santa Catarina ,","place":["Brazil"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4298-8649","authenticated-orcid":false,"given":"Caroline","family":"de Oliveira Fischer Bacca","sequence":"additional","affiliation":[{"name":"Medical Sciences Research Center, University Center for the Development of the Alto Vale do Itaja\u00ed , Rio do Sul, Santa Catarina ,","place":["Brazil"]},{"name":"Regional Alto Vale Hospital , Rio do Sul, Santa Catarina ,","place":["Brazil"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,3,14]]},"reference":[{"key":"2026091504183163800_xuag083-B1","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.1016\/j.jacc.2021.12.011","article-title":"2022 AHA\/ACC\/HFSA Guideline for the Management of Heart Failure: Executive Summary: A Report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"79","author":"Heidenreich","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"2026091504183163800_xuag083-B2","doi-asserted-by":"publisher","first-page":"3627","DOI":"10.1093\/eurheartj\/ehad195","article-title":"2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"44","author":"McDonagh","year":"2023","journal-title":"Eur Heart J"},{"key":"2026091504183163800_xuag083-B3","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1016\/j.jacc.2023.03.393","article-title":"2023 ACC expert consensus decision pathway on management of heart failure with preserved ejection fraction: a report of the American College of Cardiology solution set oversight committee","volume":"81","author":"Kittleson","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"2026091504183163800_xuag083-B4","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.cardfail.2021.01.022","article-title":"Universal definition and classification of heart failure: a report of the heart failure society of America, heart failure association of the European Society of Cardiology, Japanese heart failure society and writing committee of the universal definition of heart failure","volume":"27","author":"Bozkurt","year":"2021","journal-title":"J Card Fail"},{"key":"2026091504183163800_xuag083-B5","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1016\/S0140-6736(23)02756-3","article-title":"Heart failure with preserved ejection fraction: everything the clinician needs to know","volume":"403","author":"Campbell","year":"2024","journal-title":"Lancet Lond Engl"},{"key":"2026091504183163800_xuag083-B6","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1056\/NEJMcp2305181","article-title":"Heart failure with preserved ejection fraction","volume":"392","author":"Cannata","year":"2025","journal-title":"N Engl J Med"},{"key":"2026091504183163800_xuag083-B7","doi-asserted-by":"publisher","first-page":"102637","DOI":"10.1016\/j.jchf.2025.102637","article-title":"Nonsteroidal and steroidal mineralocorticoid antagonists: rationale, evidence, and unanswered questions","volume":"13","author":"Harrington","year":"2025","journal-title":"JACC Heart Fail"},{"key":"2026091504183163800_xuag083-B8","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1093\/eurheartj\/ehaa736","article-title":"Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine","volume":"42","author":"Agarwal","year":"2021","journal-title":"Eur Heart J"},{"key":"2026091504183163800_xuag083-B9","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions","author":"Higgins","year":"2024"},{"key":"2026091504183163800_xuag083-B10","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"2026091504183163800_xuag083-B11","doi-asserted-by":"publisher","first-page":"777","DOI":"10.7326\/M14-2385","article-title":"The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations","volume":"162","author":"Hutton","year":"2015","journal-title":"Ann Intern Med"},{"key":"2026091504183163800_xuag083-B12","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"Rob 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"2026091504183163800_xuag083-B13","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1016\/j.cardfail.2011.04.007","article-title":"Results of the randomized aldosterone antagonism in heart failure with preserved ejection fraction trial (RAAM-PEF)","volume":"17","author":"Deswal","year":"2011","journal-title":"J Card Fail"},{"key":"2026091504183163800_xuag083-B14","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1001\/jama.2013.905","article-title":"Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: the Aldo-DHF randomized controlled trial","volume":"309","author":"Edelmann","year":"2013","journal-title":"JAMA"},{"key":"2026091504183163800_xuag083-B15","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1016\/j.amjcard.2012.05.049","article-title":"Usefulness of matrix metalloproteinase-9 plasma levels to identify patients with preserved left ventricular systolic function after acute myocardial infarction who could benefit from eplerenone","volume":"110","author":"Kampourides","year":"2012","journal-title":"Am J Cardiol"},{"key":"2026091504183163800_xuag083-B16","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1016\/j.jacc.2016.07.763","article-title":"Effect of aldosterone antagonism on exercise tolerance in heart failure with preserved ejection fraction","volume":"68","author":"Kosmala","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"2026091504183163800_xuag083-B17","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1016\/j.cardfail.2014.05.010","article-title":"Effects of spironolactone treatment in elderly women with heart failure and preserved left ventricular ejection fraction","volume":"20","author":"Kurrelmeyer","year":"2014","journal-title":"J Card Fail"},{"key":"2026091504183163800_xuag083-B18","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1056\/NEJMoa1313731","article-title":"Spironolactone for heart failure with preserved ejection fraction","volume":"370","author":"Pitt","year":"2014","journal-title":"N Engl J Med"},{"key":"2026091504183163800_xuag083-B19","doi-asserted-by":"publisher","first-page":"e016239","DOI":"10.1161\/JAHA.119.016239","article-title":"Spironolactone in atrial fibrillation with preserved cardiac fraction: the IMPRESS-AF trial","volume":"9","author":"Shantsila","year":"2020","journal-title":"J Am Heart Assoc"},{"key":"2026091504183163800_xuag083-B20","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1056\/NEJMoa2407107","article-title":"Finerenone in heart failure with mildly reduced or preserved ejection fraction","volume":"391","author":"Solomon","year":"2024","journal-title":"N Engl J Med"},{"key":"2026091504183163800_xuag083-B21","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1038\/nrcardio.2017.65","article-title":"Epidemiology of heart failure with preserved ejection fraction","volume":"14","author":"Dunlay","year":"2017","journal-title":"Nat Rev Cardiol"},{"key":"2026091504183163800_xuag083-B22","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1016\/j.cardfail.2025.07.007","article-title":"HF STATS 2025: Heart failure epidemiology and outcomes statistics An updated 2025 report from the heart failure society of America","volume":"32","author":"Fonarow","year":"2026","journal-title":"J Card Fail"},{"key":"2026091504183163800_xuag083-B23","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1009492","article-title":"Eplerenone in patients with systolic heart failure and mild symptoms","volume":"364","author":"Zannad","year":"2011","journal-title":"N Engl J Med"},{"key":"2026091504183163800_xuag083-B24","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized aldactone evaluation study investigators","volume":"341","author":"Pitt","year":"1999","journal-title":"N Engl J Med"},{"key":"2026091504183163800_xuag083-B25","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1093\/eurheartj\/ehaf675","article-title":"Benefit of early initiation of disease-modifying therapy in community-based patients with suspected heart failure","volume":"47","author":"Docherty","year":"2026","journal-title":"Eur Heart J"},{"key":"2026091504183163800_xuag083-B26","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1016\/S0140-6736(24)01733-1","article-title":"Mineralocorticoid receptor antagonists in heart failure: an individual patient level meta-analysis","volume":"404","author":"Jhund","year":"2024","journal-title":"Lancet Lond Engl"},{"key":"2026091504183163800_xuag083-B27","doi-asserted-by":"publisher","first-page":"5406","DOI":"10.3390\/jcm14155406","article-title":"Current treatment of heart failure with preserved ejection fraction","volume":"14","author":"Riccardi","year":"2025","journal-title":"J Clin Med"},{"key":"2026091504183163800_xuag083-B28","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1007\/s10741-025-10524-z","article-title":"Heart failure with preserved ejection fraction therapeutics: in search of the pillars","volume":"30","author":"Rafei","year":"2025","journal-title":"Heart Fail Rev"},{"key":"2026091504183163800_xuag083-B29","doi-asserted-by":"publisher","first-page":"2373","DOI":"10.3390\/jcm12062373","article-title":"Digital health technologies for post-discharge care after heart failure hospitalisation to relieve symptoms and improve clinical outcomes","volume":"12","author":"Krzesi\u0144ski","year":"2023","journal-title":"J Clin Med"},{"key":"2026091504183163800_xuag083-B30","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.pcad.2024.01.009","article-title":"New models for heart failure care delivery","volume":"82","author":"Xia","year":"2024","journal-title":"Prog Cardiovasc Dis"}],"container-title":["European Journal of Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurjhf\/advance-article-pdf\/doi\/10.1093\/ejhf\/xuag083\/67359250\/xuag083.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurjhf\/article-pdf\/28\/3\/473\/67359250\/xuag083.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurjhf\/article-pdf\/28\/3\/473\/67359250\/xuag083.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T08:23:23Z","timestamp":1789460603000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurjhf\/article\/28\/3\/473\/8524196"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":30,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,3,14]]},"published-print":{"date-parts":[[2026,9,15]]}},"URL":"https:\/\/doi.org\/10.1093\/ejhf\/xuag083","relation":{},"ISSN":["1388-9842","1879-0844"],"issn-type":[{"value":"1388-9842","type":"print"},{"value":"1879-0844","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,3]]},"published":{"date-parts":[[2026,3]]}}}